Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer

Abstract

The insulinoma-associated 1 (INSM1) gene is expressed exclusively during early embryonal development, but has been found re-expressed at high levels in neuroendocrine tumors. The regulatory region of the INSM1 gene is therefore a potential candidate for regulating expression of a therapeutic gene in transcriptionally targeted cancer gene therapy against neuroendocrine tumors. We analyzed expression of a reporter gene from a 1.7 kb region of the INSM1 promoter in a large number of small-cell lung cancer (SCLC) cell lines. This INSM1 promoter region showed very high levels of expression in most of the SCLC cell lines and expression was absent in cell lines of non-neuroendocrine origin. Inclusion of the general transcriptional enhancer from SV40 compromised the specificity of the promoter and did not enhance transcription in most of the SCLC cell lines. For comparison, the region of the gastrin releasing peptide (GRP) previously suggested for SCLC gene therapy was analyzed in a similar manner. High expression was observed for a number of cell lines, but unlike for the INSM1 promoter, reporter gene expression from the GRP promoter did not correlate to the relative GRP mRNA levels, demonstrating that this region may not contain all necessary regulatory elements. Expression of the suicide gene herpes simplex virus thymidine kinase (HSV-TK) from the INSM1 promoter in combination with treatment with the prodrug ganciclovir (GCV) caused a significant increase in GCV sensitivity specifically in INSM1-expressing cell lines. The INSM1 promoter is therefore a potential novel tool for transcriptionally targeted gene therapy for neuroendocrine tumors.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Simon M, Argiris A, Murren JR . Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004; 49: 119–133.

    Article  Google Scholar 

  2. Turrisi AT, Sherman CA . The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer 2002; 38: 279–291.

    Article  CAS  Google Scholar 

  3. Robson T, Hirst DG . Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2003: 110–137.

    Article  Google Scholar 

  4. Rygaard K, Vindeløv LL, Spang-Thomsen M . Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts. Int J Cancer 1993; 54: 144–152.

    Article  CAS  Google Scholar 

  5. Nishino K, Osaki T, Kumagai T, Kijima T, Tachibana I, Goto H et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer 2001; 91: 851–856.

    Article  CAS  Google Scholar 

  6. Kumagai T, Tanio Y, Osaki T, Hosoe S, Tachibana I, Ueno K et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res 1996; 56: 354–358.

    CAS  PubMed  Google Scholar 

  7. Song JS, Kim HP . Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line. Oncol Rep 2004; 12: 443–447.

    PubMed  Google Scholar 

  8. Coulson JM, Stanley J, Woll PJ . Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer. Br J Cancer 1999; 80: 1935–1944.

    Article  CAS  Google Scholar 

  9. Pass MK, Quintini G, Zarn JA, Zimmermann SM, Sigrist JA, Stahel RA . The 5′-flanking region of human CD24 gene has cell-type-specific promoter activity in small-cell lung cancer. Int J Cancer 1998; 78: 496–502.

    Article  CAS  Google Scholar 

  10. Tanaka M, Inase N, Miyake S, Yoshizawa Y . Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res 2001; 21: 291–294.

    CAS  PubMed  Google Scholar 

  11. Miyake Y, Kodama T, Yamaguchi K . Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994; 54: 2136–2140.

    CAS  PubMed  Google Scholar 

  12. Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M et al. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 2002; 128: 633–640.

    Article  CAS  Google Scholar 

  13. Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y . Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int J Cancer 2000; 85: 716–719.

    Article  CAS  Google Scholar 

  14. Morimoto E, Inase N, Mlyake S, Yoshizawa Y . Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res 2001; 21: 329–331.

    CAS  PubMed  Google Scholar 

  15. Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003; 63: 1943–1953.

    CAS  Google Scholar 

  16. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790–13795.

    Article  CAS  Google Scholar 

  17. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784–13789.

    Article  CAS  Google Scholar 

  18. Goto Y, De Silva MG, Toscani A, Prabhakar BS, Notkins AL, Lan MS . A novel human insulinoma-associated cDNA, IA-1, encodes a protein with ‘zinc-finger’ DNA-binding motifs. J Biol Chem 1992; 267: 15252–15257.

    CAS  PubMed  Google Scholar 

  19. Lan MS, Russell EK, Lu J, Johnson BE, Notkins AL . IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res 1993; 53: 4169–4171.

    CAS  PubMed  Google Scholar 

  20. Zhu M, Breslin MB, Lan MS . Expression of a novel zinc-finger cDNA, IA-1, is associated with rat AR42J cells differentiation into insulin-positive cells. Pancreas 2002; 24: 139–145.

    Article  Google Scholar 

  21. Breslin MB, Zhu M, Notkins AL, Lan MS . Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. Nucleic Acids Res 2002; 30: 1038–1045.

    Article  CAS  Google Scholar 

  22. Xie J, Cai T, Zhang H, Lan MS, Notkins AL . The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. Genomics 2002; 80: 54–61.

    Article  CAS  Google Scholar 

  23. Lan MS, Li Q, Lu J, Modi WS, Notkins AL . Genomic organization, 5′-upstream sequence, and chromosomal localization of an insulinoma-associated intronless gene, IA-1. J Biol Chem 1994; 269: 14170–14174.

    CAS  PubMed  Google Scholar 

  24. Li Q, Notkins AL, Lan MS . Molecular characterization of the promoter region of a neuroendocrine tumor marker, IA-1. Biochem Biophys Res Commun 1997; 236: 776–781.

    Article  CAS  Google Scholar 

  25. Breslin MB, Zhu M, Lan MS . NeuroD1/E47 regulates the E-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system. J Biol Chem 2003; 278: 38991–38997.

    Article  CAS  Google Scholar 

  26. Li S, MacLaughlin FC, Fewell JG, Gondo M, Wang J, Nicol F et al. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid. Gene Therapy 2001; 8: 494–497.

    Article  CAS  Google Scholar 

  27. Park CW, Park YM, Lee GT, Lee Y, Woo S, Cha JY et al. Targeting of therapeutic gene expression to the liver by using liver-type pyruvate kinase proximal promoter and the SV40 viral enhancer active in multiple cell types. Biochem Biophys Res Commun 2004; 314: 131–137.

    Article  CAS  Google Scholar 

  28. Yazawa K, Fisher WE, Brunicardi FC . Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783–789.

    Article  Google Scholar 

  29. Fillat C, Carrio M, Cascante A, Sangro B . Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3: 13–26.

    Article  CAS  Google Scholar 

  30. Nagalla SR, Spindel ER . Functional analysis of the 5′-flanking region of the human gastrin-releasing peptide gene in small cell lung carcinoma cell lines. Cancer Res 1994; 54: 4461–4467.

    CAS  PubMed  Google Scholar 

  31. Graessmann M, Menne J, Liebler M, Graeber I, Graessmann A . Helper activity for gene expression, a novel function of the SV40 enhancer. Nucleic Acids Res 1989; 17: 6603–6612.

    Article  CAS  Google Scholar 

  32. Dean DA . Import of plasmid DNA into the nucleus is sequence specific. Exp Cell Res 1997; 230: 293–302.

    Article  CAS  Google Scholar 

  33. Dean DA, Dean BS, Muller S, Smith LC . Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713–722.

    Article  CAS  Google Scholar 

  34. Young JL, Benoit JN, Dean DA . Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature. Gene Therapy 2003; 10: 1465–1470.

    Article  CAS  Google Scholar 

  35. Mermod N, Williams TJ, Tjian R . Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988; 332: 557–561.

    Article  CAS  Google Scholar 

  36. Richards CA, Austin EA, Huber BE . Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881–893.

    Article  CAS  Google Scholar 

  37. Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S et al. Molecular genetics of malignant insulinoma. Anticancer Res 1996; 16: 1707–1717.

    CAS  PubMed  Google Scholar 

  38. Cesen-Cummings K, Fernstrom MJ, Malkinson AM, Ruch RJ . Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. Carcinogenesis 1998; 19: 61–67.

    Article  CAS  Google Scholar 

  39. Qiao J, Black ME, Caruso M . Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11: 1569–1576.

    Article  CAS  Google Scholar 

  40. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GL et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85–92.

    CAS  Google Scholar 

  41. Ammerpohl O, Thormeyer D, Khan Z, Appelskog IB, Gojkovic Z, Almqvist PM et al. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 2004; 324: 8–14.

    Article  CAS  Google Scholar 

  42. Hansen LT, Lundin C, Helleday T, Poulsen HS, Sorensen CS, Petersen LN et al. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 2003; 40: 157–164.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the Danish Cancer Society, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Aase and Ejnar Danielsens Foundation and the AP Møller Foundation for the Advancement of Medical Science.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H S Poulsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, N., Pedersen, M., Lan, M. et al. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 13, 375–384 (2006). https://doi.org/10.1038/sj.cgt.7700887

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700887

Keywords

This article is cited by

Search

Quick links